Yang Y, Wang Z, Gao B, et al. - Researchers sought to evaluate clinical outcomes using galcanezumab, a novel monoclonal antibody that target to calcitonin gene-related peptide and was identified as effective treatment for preventing migraine and episodic cluster headache in multiple randomized clinical trials and for reducing headache frequency. They conducted a systematical search in PubMed and Embase on Cochrane Central Register of Controlled Trials from the earliest date to August 1, 2019, and included seven studies with 3,889 patients. Outcomes support the efficacy of galcanezumab in significantly reducing monthly headache frequency compared with placebo for the treatment of migraine and episodic cluster headache. Providing 120 mg vs 240 mg led to the attainment of the same treatment efficacy but with a lower risk for adverse effects for the treatment of migraine. For the prevention of episodic cluster headache, 300 mg per month galcanezumab is identified as effective with no significantly increased adverse events.